Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira® - Trial NCT06005532
Access comprehensive clinical trial information for NCT06005532 through Pure Global AI's free database. This Phase 3 trial is sponsored by Mabscale, LLC and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 494 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mabscale, LLC
Timeline & Enrollment
Phase 3
Oct 01, 2023
Dec 01, 2025
Primary Outcome
The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by ≥75% from the baseline level assessed by the PASI index),Proportion of patients with positive antibody titer to Adalimumab,Percentage of patients who have neutralizing antibodies to Adalimumab
Summary
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy,
 immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to
 Humira®.
 
 The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab
 (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis
 of moderate and severe degree.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06005532
Non-Device Trial